Brokerages Anticipate Voyager Therapeutics Inc (VYGR) Will Post Quarterly Sales of $3.00 Million
Brokerages predict that Voyager Therapeutics Inc (NASDAQ:VYGR) will announce sales of $3.00 million for the current quarter, Zacks reports. Three analysts have provided estimates for Voyager Therapeutics’ earnings, with the lowest sales estimate coming in at $2.00 million and the highest estimate coming in at $5.00 million. Voyager Therapeutics reported sales of $940,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 219.1%. The firm is expected to issue its next earnings results on Thursday, May 9th.
According to Zacks, analysts expect that Voyager Therapeutics will report full year sales of $14.01 million for the current financial year, with estimates ranging from $8.00 million to $20.00 million. For the next year, analysts forecast that the firm will post sales of $20.63 million, with estimates ranging from $8.00 million to $40.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, February 26th. The company reported ($0.70) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.70). Voyager Therapeutics had a negative net margin of 648.40% and a negative return on equity of 81.63%.
Shares of NASDAQ VYGR opened at $17.71 on Thursday. Voyager Therapeutics has a 12-month low of $7.76 and a 12-month high of $27.00. The stock has a market capitalization of $577.89 million, a price-to-earnings ratio of -6.44 and a beta of 2.58.
Large investors have recently bought and sold shares of the company. Metropolitan Life Insurance Co. NY raised its position in shares of Voyager Therapeutics by 449.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $85,000 after buying an additional 7,401 shares during the last quarter. Bank of America Corp DE raised its position in shares of Voyager Therapeutics by 211.0% in the fourth quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock valued at $100,000 after buying an additional 7,217 shares during the last quarter. AlphaCrest Capital Management LLC acquired a new position in shares of Voyager Therapeutics in the fourth quarter valued at approximately $102,000. Weiss Multi Strategy Advisers LLC raised its position in shares of Voyager Therapeutics by 10.0% in the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 11,000 shares of the company’s stock valued at $103,000 after buying an additional 1,000 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of Voyager Therapeutics by 66.8% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,380 shares of the company’s stock valued at $101,000 after buying an additional 4,559 shares during the last quarter. 85.86% of the stock is owned by institutional investors and hedge funds.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Featured Story: What kind of dividend yield to CEF’s pay?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.